Open AccessHemorrhagic pericardial effusion following treatment with infliximab: A case report and literature review
Author(s) -
Hui Li,
Hui Xing,
Chen Hu,
Bai-Yang Sun,
Shuang Wang,
Wanying Li,
Bo Qü
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i25.7593
Subject(s) - medicine , infliximab , pericardial effusion , surgery , tumor necrosis factor alpha
Infliximab (IFX) is an anti-tumor necrosis factor alpha (TNF-α) agent that is widely used for the management of a variety of autoimmune and inflammatory diseases, including Crohn's disease (CD). As a result of its increasing administration, new complications have emerged. Hemorrhagic pericardial effusion, secondary to IFX therapy, is a rare but life-threatening complication.